Łabuzek Krzysztof, Liber Sebastian, Suchy Dariusz, Okopień Bogusław
Department of Internal Medicine, Clinical Pharmacology, Medical University of Silesia, Katowice, Poland.
Int J Clin Pharmacol Ther. 2013 Jun;51(6):517-24. doi: 10.5414/CP201878.
In this case report, we describe a patient with Dercum's disease who was successfully managed with metformin. The administration of metformin reduced pain intensity from 9/10 to 3/10 and favorably affected the profile of inflammatory cytokines (i.e., TNF a, IL-1β, IL-6, and IL-10), adipokines (i.e., adiponectin, leptin, and resistin), and β-endorphin. Because each variable was affected moderately by the drug, in the range of 20 - 30%, it follows that these effects are additive, i.e., they act independently of each other. However, taking into account advances in the pharmacology of metformin, it seems that other phenomena, such as modulation of synaptic plasticity, activation of microglia, and autophagy of the afferents supplying painful lipomas should be taken into consideration. Nonetheless, metformin deserves further exploration in the biology of pain.
在本病例报告中,我们描述了一名患有德库姆病的患者,其通过二甲双胍成功得到治疗。二甲双胍的使用将疼痛强度从9/10降至3/10,并对炎性细胞因子(即肿瘤坏死因子α、白细胞介素-1β、白细胞介素-6和白细胞介素-10)、脂肪因子(即脂联素、瘦素和抵抗素)以及β-内啡肽产生了有利影响。由于每个变量受该药物的影响程度适中,在20% - 30%的范围内,因此这些作用是相加的,即它们彼此独立起作用。然而,考虑到二甲双胍药理学的进展,似乎还应考虑其他现象,如突触可塑性的调节、小胶质细胞的激活以及供应疼痛性脂肪瘤的传入神经的自噬。尽管如此,二甲双胍在疼痛生物学方面仍值得进一步探索。